Categories: News

Sentry unveils new 340B BI reporting solution, the most powerful analytics tool on the market

DEERFIELD BEACH, Fla., May 19, 2021 /PRNewswire/ — Sentry Data Systems, Inc., the nation’s leader in pharmacy procurement, compliance and utilization management, today introduced the 340B BI tool as a breakthrough for customers who need more transparency from their data to counter increased complexity in their 340B programs. Sentry 340B BI seamlessly integrates with its customers’ continuously updated data — including ordering platforms — and is designed to allow even non-experts to run advanced business intelligence reports.

Sentry 340B BI is designed to allow even non-experts to run advanced business intelligence reports.

“Sentry 340B BI changes the game by providing easy access to sophisticated, robust data sets, dashboards and reporting that uncover valuable insights to help covered entities maximize their benefits,” said Travis Leonardi, RPh, founder and CEO of Sentry Data Systems. “By being fully customizable and easy to use, our new solution goes beyond anything offered by our competitors and represents the next level in analytics reporting for our customers.”

Sentry 340B BI aggregates customers’ data and populates it into an easy-to-use analytics and reporting environment. It’s a highly flexible, advanced solution designed to be readily accessible, with drag-and-drop functionality – without the need to enlist a consultant or analyst to write queries or build reports. The result is a robust visualization of a customer’s 340B program.

The tool is designed to integrate seamlessly with Sentry’s 340B platform, with the abilities to roll up numbers from mixed-use and contract pharmacy settings, and easily compare pharmacy data at an enterprise level. It allows for nearly limitless manipulation of information, with the ability to search and arrange data by drug manufacturer, NDC number and location, among other fields, to yield metrics on key concerns such as drug spending, claims volume, dispensations and revenue.

For covered entities, the new 340B BI tool has powerful applications for managing audits, changes from drug manufacturers, vertical integration and hospital consolidation.

About Sentry Data Systems, Inc.
Sentry Data Systems, Inc. is a pioneer in providing technology solutions that help healthcare providers address their three biggest challenges: reducing total cost of care, managing compliance and producing better quality. Thousands of hospitals and care locations across the country rely on Sentry’s integrated platform for their solutions, which provide decision support for millions of unique patients and have helped hospital systems and IDNs realize billions of dollars in documented savings.

Media Contact:
Michelle Hornberger, MHSA, FACHE
Vice President of Marketing
mhornberger@sentryds.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/sentry-unveils-new-340b-bi-reporting-solution-the-most-powerful-analytics-tool-on-the-market-301294459.html

SOURCE Sentry Data Systems, Inc.

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

3 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

5 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

5 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

5 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

5 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

5 hours ago